News
   
Professor LU Bing Won the Second Prize of National Scientific and Technological Progress
  审核人:

On January 8, 2018, National Awards for Science and Technology of 2017 were held in the Great Hall of the People, Beijing. Professor LU Bing from GMU won the second prize for his participation and contribution made in the project, Research on Key Technologies of  Precise Radiotherapy of Lung Cancer and Its clinical Application.

Professor LU has engaged in clinic and its related researches for nearly 30 years, especially deeply in the researches of radiotherapy, chemotherapy, molecular targeted therapy and standardized comprehensive treatment of lung cancer. He took the lead in carrying on internationally advanced and new technologies of precise radiotherapy of lung cancer and other breast tumors, including three-dimensional conformal line, stereotaxis(X-knife), intensity modulated radiation, and image-guidance, and he used the new result of chemotherapy and molecular targeted therapy and explored new comprehensive therapy.

Professor LU Bing’s research on radiotherapy intervention in terminal NSCLC (non-small cell lung cancer), has increased the survival rate of patients with distant metastasis, from 6% to 10%, which was published on BMC Cancer and Int J Radiat Oncol Biol Phys, American official magazine of radiation oncology, as the Issue Highlights of that day. Catheryn M. Yashar, a professor of division of radiation and cancer biology who worked in the cancer center of Moores, University of California at San Diego, said that“This kind of strategy may have some role in palliationat present, but will probably become more important if systemic therapy could improve.”It was published by Chinese Journal of Radiation Oncology as “research topic”, selected as the 2011 annual “important research issue”. Professor Yin Weibo, a leading authority of radiation oncology, wrote editor’s notes for his research. The research was also selected in Standardized Training Program for Residents of the National health and Family Planning Commission— Radiation Oncology.